Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Официальное название

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Moderate-to-Severe ARDS: A Phase III Clinical Trial

Обзор

To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).

Подробное описание

This is a Phase III, multicenter, randomized, double-blinded, placebo-controlled trial for the treatment of moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).

Вмешательства

• Биопрепарат ExoFlo
  Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
• Другое Intravenous normal saline
  Placebo

Первичные конечные точки

• Evaluation of 60-day All-cause Mortality [Срок оценки: 60 days]

Вторичные конечные точки (5)

• Time to death [Срок оценки: 60 days]
• Ventilator-free days (VFDs) [Срок оценки: Day 29]
• Oxygen free days [Срок оценки: Day 29]
• ICU free days [Срок оценки: Day 29]
• Incidence of Treatment Emergent Serious Adverse Events (TESAEs) [Срок оценки: 61 days]

Критерии участия

Критерии включения

• Men and women aged 18-75 years of age
• Presence of the following criteria for moderate to severe ARDS as defined by the Berlin Criteria within 24 hours of the first infustion:

• Onset within 7 days of known clinical insult or requiring increasing respiratory rate, increasing oxygen flows, or increased work of breathing, and
• Bilateral lung opacities not fully explained by pleural effusions, atelectasis, or nodules, and
• PaO2/FiO2 (P/F ratio) ≤ 200 mm Hg, and
• Invasive or noninvasive ventilation with a minimum PEEP 5 cm H2O or minimum of continuous positive airway pressure (CPAP) 5 cm H2O, or High Flow Nasal Oxygen at ≥ 30 L/min, and
• Respiratory failure not fully explained by cardiac failure or fluid overload.

Критерии исключения

• Lack of signed and dated informed consent form (either by the individual or by the individual's healthcare proxy).
• Stated unwillingness to comply with all study procedures and availability for the duration of the study
• Vulnerable populations such as pregnant patients, children, individuals with severe physical or mental disabilities who cannot provide meaningful consent.
• Active malignancy requiring treatment within the last two years, with the exception of non-melanoma skin cancers.
• Major physical trauma in the last 2 days, including motor vehicle accidents, assaults, mechanical falls with sequelae of significant bleeding or craniofacial bruising, and surgeries, such that not one or more injury may be undiagnosed at time of screening.
• Duration of mechanical ventilation exceeds 3 days or 72 hours from diagnosis of ARDS.
• ALT or AST > 8 x Upper Limit of Normal (ULN).
• Documented history of cirrhosis.
• DNR order, as in electing not to receive chest compressions, cardiac defibrillation, cardiac drugs, or intubation.
• Moribund-expected survival < 24 hours.
• Severe metabolic disturbances at randomization (e.g., ketoacidosis, pH < 7.2)
• Patient currently connected to Extracorporeal Membrane Oxygenation at initiation of screening.
• If the candidate, either a male or female of reproductive potential, is unwilling to two methods of highly effective birth control contraception such as condoms with oral contraceptive pill or choose to remain abstinent if already practicing abstinence during the screening period. The required duration of usage of double method OR maintenance of abstinence must include the time from the beginning of the screening period until Day 61, day of withdrawal or early termination
• Use of investigational COVID-19 agents or any other investigational agents within 30 days prior to the first dose.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Тройное слепое

Основная цель

Лечение

Центры проведения

США · 32 центра

• Direct Biologics Investigational Site — Phoenix
• Direct Biologics Investigational Site — Little Rock
• Direct Biologics Investigational Site — Davis
• Direct Biologics Investigational Site — Irvine
• Direct Biologics Investigational Site — Sacramento
• Direct Biologics Investigational Site — Washington D.C.
• Direct Biologics Investigational Site — Jacksonville
• Direct Biologics Investigational Site — Boise
• … и ещё 24 центра

Идентификаторы

NCT: NCT05354141 · DB-EF-PHASEIII-0001

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗